首页> 外文期刊>Vaccine >Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice
【24h】

Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice

机译:杀死乳酸杆菌DK128对增强T辅助1型免疫反应的佐剂效应及流感疫苗接种在正常和CD4缺陷小鼠中的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Lactic acid bacteria Lactobacillus casei DK128 isolated from fermented vegetable foods was suggested to stimulate innate immune responses. Here, we investigated whether heat-killed DK128 would exhibit adjuvant effects on enhancing the efficacy of influenza vaccination. Immunization of mice with split influenza virus vaccine in the presence of heat-killed DK128 induced significantly higher levels of both IgG1 and IgG2c isotype antibodies than those by vaccine only. A single dose DK128-adjuvanted influenza vaccination conferred higher efficacy of protection, as evidenced by intact lung function, less weight loss, enhanced clearance of lung viral loads, and lower levels of inflammatory cytokines and infiltrates. Immunization of CD4 T cell-knockout (CD4KO) mice with influenza vaccine and DK128, but not with vaccine alone, induced isotype-switched IgG antibodies and protection against lethal challenge in CD4KO mice. The results in this study suggest heat-killed DK128 as a potential vaccine adjuvant, promoting the induction of IgG isotype switching in CD4-deficient condition and enhancing protective efficacy of split influenza vaccination in immunocompromised and immune-competent subjects. (C) 2020 Elsevier Ltd. All rights reserved.
机译:提出了从发酵蔬菜食品中分离的乳酸菌乳酸杆菌酪蛋白酶DK128刺激了天生的免疫反应。在这里,我们研究了热杀死的DK128是否对提高流感疫苗接种的疗效表现出佐剂作用。在热杀死的DK128存在下具有分裂流感病毒疫苗的小鼠免疫诱导IgG1和IgG2C同种型抗体的显着较高,仅通过疫苗。单一剂量DK128辅助流感疫苗接种疫苗接种促使的疗效较高,如完整的肺功能,减轻重量损失,增强的肺病毒载荷,较低水平的炎症细胞因子和浸润。用流感疫苗和DK128免疫CD4 T细胞敲除(CD4KO)小鼠,但单独使用疫苗,诱导同种型切换IgG抗体和CD4KO小鼠中的致死攻击。本研究的结果表明,热杀死的DK128作为潜在的疫苗佐剂,促进IgG同种型切换的CD4缺乏条件,提高分裂流感疫苗接种在免疫抑制和免疫主体受试者中的保护效果。 (c)2020 elestvier有限公司保留所有权利。

著录项

  • 来源
    《Vaccine》 |2020年第36期|共10页
  • 作者单位

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

    Dankook Univ Dept Anim Resource Sci Cheonan Chungnam South Korea;

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Ctr Inflammat Immun &

    Infect Atlanta GA 30303 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

    Lactic acid bacteria; Adjuvant; Influenza vaccine;

    机译:乳酸菌;佐剂;流感疫苗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号